Serum C-reactive protein and procalcitonin levels in non-small cell lung cancer patients Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012
Serum levels of STR-3 and TIMP-2 in lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002
IGF-I and IGFBP-3 concentrations in the blood serum and lung cancer risk Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007
The study on the association of serum C-reactive protein level with the risk of lung cancer Source: Annual Congress 2009 - Various diagnostic aspects in lung cancer and rare lung tumours Year: 2009
Serum levels of interleukin 8 and plasma levels of osteopontin in patients with non-small cell lung cancer during chemotherapy Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
The clinical significance of serum osteoprotegerin (OPG) and pro-gastrin-releasing peptide (ProGRP) concentrations in lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 318s Year: 2004
Usefulness of serum procalcitonin in lung cancer patients with elevated serum C-reactive protein level Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
Fucosylation of serum glycoproteins in lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 458s Year: 2005
Soluble sPD-L1 plasma concentrations in a series of 95 lung cancer patients Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018
Plasma D-dimer level and stage of primary lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 250s Year: 2003
Plasma levels of soluble urokinase plasminogen activator receptor (suPAR) as a possible biomarker for lung cancer and/or COPD Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016
A serum level of IGF-I, IGF-II and IGFBP-3 in patients with small cell lung cancer (SCLC) during chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 86s Year: 2006
The clinical significance of serum VEGF C, VEGF D and sVEGFR2 concentration in lung cancer Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007
Human epididymis protein 4 (HE4): a potential biomarker for IPF Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers Year: 2020
Plasma leptin levels in nonsmall cell lung carcinoma (NSCLC) patients at the time of the diagnosis Source: Eur Respir J 2001; 18: Suppl. 33, 65s Year: 2001
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
A serum level of IGF-I and IGFBP-3 in patients with lung cancer during chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 329s Year: 2005
Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
Elevated level of circulating matrix metalloproteinase-9 in non-small lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 229s Year: 2002
Serum levels of sFas and sFasL during chemotherapy of lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 329s Year: 2005